Trimetazidine Alleviates Bleomycin-Induced Pulmonary Fibrosis by Targeting the Long Noncoding RNA CBR3-AS1-Mediated miRNA-29 and Resistin-Like Molecule alpha 1: Deciphering a Novel Trifecta Role of LncRNA CBR3-AS1/miRNA-29/FIZZ1 Axis in Lung Fibrosis
Drug Design, Development and Therapy · 2024
DOI: 10.2147/dddt.s463626 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2024. Verfasst von Abdullah R Alzahrani und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia. Hauptthemen laut MEDLINE: Bleomycin, RNA, Long Noncoding, MicroRNAs, Pulmonary Fibrosis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Introduction
Pulmonary fibrosis (PF) and tissue remodeling can greatly impair pulmonary function and often lead to fatal outcomes. Methodology: In the present study, we explored a novel molecular interplay of long noncoding (Lnc) RNA CBR3-AS1/ miRNA-29/ FIZZ1 axis in moderating the inflammatory processes, immunological responses, and oxidative stress pathways in bleomycin (BLM)-induced lung fibrosis. Furthermore, we investigated the pharmacological potential of Trimetazidine (TMZ) in ameliorating lung fibrosis.
Results
Our results revealed that the BLM-treated group exhibited a significant upregulation in the expression of epigenetic regulators, lncRNA CBR3-AS1 and FIZZ1, compared to the control group (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
- Department of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Zoology Department, Faculty of Science, Port Said University, Port Said, Egypt.
- Department of Histology and Cell Biology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia.
- Department of Chest Diseases, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
ORCID-Profile: Dalia Alaa El-Din Aly El-Waseef, Soha M Y Mohamed, Alaa H Falemban, Nasser Attia Elhawary, Essa M Saied
Zitieren
APA
Alzahrani, A. R., Mohamed, D. I., Abo Nahas, H. H., Alaa El-Din Aly El-Waseef, D., Altamimi, A. S., Youssef, I. H., Ibrahim, I. A. A., Mohamed, S. M. Y., Sabry, Y. G., Falemban, A. H., Elhawary, N. A., Bamagous, G. A., Jaremko, M., & Saied, E. M. (2024). Trimetazidine Alleviates Bleomycin-Induced Pulmonary Fibrosis by Targeting the Long Noncoding RNA CBR3-AS1-Mediated miRNA-29 and Resistin-Like Molecule alpha 1: Deciphering a Novel Trifecta Role of LncRNA CBR3-AS1/miRNA-29/FIZZ1 Axis in Lung Fibrosis. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s463626
Vancouver
Alzahrani AR, Mohamed DI, Abo Nahas HH, Alaa El-Din Aly El-Waseef D, Altamimi AS, Youssef IH, et al. Trimetazidine Alleviates Bleomycin-Induced Pulmonary Fibrosis by Targeting the Long Noncoding RNA CBR3-AS1-Mediated miRNA-29 and Resistin-Like Molecule alpha 1: Deciphering a Novel Trifecta Role of LncRNA CBR3-AS1/miRNA-29/FIZZ1 Axis in Lung Fibrosis. Drug Design, Development and Therapy. 2024. doi:10.2147/dddt.s463626
BibTeX
@article{Alzahrani2024,
author = {Alzahrani, Abdullah R and Mohamed, Doaa I and Abo Nahas, Hebatallah H and Alaa El-Din Aly El-Waseef, Dalia and Altamimi, Abdulmalik S and Youssef, Ibrahim H and Ibrahim, Ibrahim Abdel Aziz and Mohamed, Soha M Y and Sabry, Yasmine Gamal and Falemban, Alaa H and Elhawary, Nasser Attia and Bamagous, Ghazi A and Jaremko, Mariusz and Saied, Essa M},
title = {Trimetazidine Alleviates Bleomycin-Induced Pulmonary Fibrosis by Targeting the Long Noncoding RNA CBR3-AS1-Mediated miRNA-29 and Resistin-Like Molecule alpha 1: Deciphering a Novel Trifecta Role of LncRNA CBR3-AS1/miRNA-29/FIZZ1 Axis in Lung Fibrosis},
journal = {Drug Design, Development and Therapy},
year = {2024},
doi = {10.2147/dddt.s463626}
}
EUVIMED